Vaxin changes name to Altimmune
Vaxin was first formed in 1997 to create innovative, new-generation vaccine products and technologies. Since that time, Vaxin has had steady success in developing novel vaccine candidates to address biodefense and similar public health needs, in addition to animal health.
The company made a strategic growth move earlier in 2015 by acquiring Immune Targeting Systems (ITS), a company based in the United Kingdom. This has added important new investors to the company’s syndicate.
With the acquisition, Vaxin joined the immunotherapeutics industry, which has served to increase its market, therapeutics expertise and worldwide footprint.
The new name emphasizes the newly united company’s next phase.
"The Vaxin brand has served as a superb ambassador of our vaccine product family, but the expansion of our product platform calls for a new brand," Bill Enright, president and CEO, said. "The name Altimmune reflects the novel solutions we bring to the broader biotech marketplace today. Bold emphasis on the immune system is intentional; it speaks to alternative therapies that stimulate immune responses for prevention and treatment of diseases. With some of today's most exciting research discoveries happening in this area, our new name conveys a promise to deliver essential innovation to the space."